Predictmedix Inc

Predictmedix — Investor Presentation (November 2020)

23 slides from Predictmedix's investor presentation, November 2020

  1. Slide 1: PredictMedix

    PREDICTMEDIX.COM PMED : CSE PMEDF : OTCQB

  2. Slide 2: Disclaimer and forward-looking information

    Complete disclaimer in investment memorandum This document provides a summary description of PREDICTMEDIX Inc. (“PREDICTMEDIX”), its subsidiary companies and its business and does not purport to be complete. Prospective investors are encouraged to obtain independent legal advice concerning any inves

  3. Slide 3: The Current Landscape

    The Current Landscape COVID-19 & Cannabis & Mental Virtual Infectious Alcohol Illnesses Care Diseases Impairment 3 PMED : CSE PMEDF : OTCQB

  4. Slide 4: Bringing advanced AI technology to power the HealthTech wave

    Bring advanced AI technology to power the world’s HealthTech wave It all adds up to explain why PredictMedix is $13.9B USD $1.4B USD Drug Screening Market Cannabis Screening developing its AI HealthTech Forecast for 2027 Market Forecast for 2021 $5.0B USD $13.0B USD solutions! Respiratory Disease AI

  5. Slide 5: Who We Are

    Who We Are PREDICTMEDIX is an AI (Artificial Intelligence) company developing disruptive technologies for health and safety in workplaces and healthcare. Rapid Mass Screening Remote Patient Care Using multispectral cameras and sensors to capture data A remote monitoring telehealth platform integrati

  6. Slide 6: Easy to deploy in any indoor and outdoor location

    Easy to deploy Infections including COVID-19, produce unique physiological patterns in any indoor and that our solution will detect, assess and determine the probability of that person being infected or not infected. outdoor location Workplaces, Retail, As the virus mutates, our AI will learn how ne

  7. Slide 7: First to market

    Employers, as well as law enforcement, test people for traces of cannabis, alcohol First to market and opioids. However, they cannot determine if individuals are actually impaired. Without the ability to determine impairment, it is not possible to PredictMedix first-to-market AI product accurately p

  8. Slide 8: First diagnostic tool

    Mental illness is difficult to detect at early stages. Primarily due to First diagnostic tool a lack of diagnostic tools other than standardized surveys and subjective assessment from trained healthcare practitioners. PredictMedix Mental Illness Diagnostic Screening is a disruptive AI technology tha

  9. Slide 9: Remote patient monitoring & telehealth platform

    Remote patient monitoring & telehealth platform for healthcare, LTC and employers Long Term Care (LTC) Clinical Research Large Scale and Retirement Residences Organizations (CRO) Employees Covid-19 has revealed the devastating Traditional methods of on-site monitoring Existing human resource platfor

  10. Slide 10: Putting care into telehealth

    Putting care into telehealth Wearables and Bluetooth Reward Programs Engagement tools Makes it easy for patients to share their Incentivises compliance to From video to multiple communication channels, vitals through the platform, and to give promote better outcomes and patients and practitioners, e

  11. Slide 11: Protecting IP for Future Growth

    Protecting IP for Future Growth 6 US PATENTS HAVE BEEN FILED IMPAIRMENT (1) INFECTIOUS DISEASE SYMPTOMS (1) MOBILE WELL-BEING (4) 11 PMED : CSE PMEDF : OTCQB

  12. Slide 12: The biggest and best believe in our solutions

    The biggest and best believe in our solutions Tech Mahindra PREDICTMEDIX has signed Joint Venture Indian Institute of Technology (IIT) agreements with Tech Mahindra for PREDICTMEDIX screening technology. Max Healthcare Indian Institute of Technology (IIT), renowned for training the world’s top techn

  13. Slide 13: Monthly fee model and reseller agreements

    Clients pay a monthly fee based on tiered volume of screenings providing PredictMedix with recurring monthly revenue and Flow Water, one of the fastest growing premium water multi-year contracts through a network of resellers. brands in North America, uses PredictMedix Covid-19 & Infectious Disease

  14. Slide 14: Mainstream, trade and investor media

    Mainstream, trade and investor media are actively pursuing PredictMedix for interviews and features. 14 PMED : CSE PMEDF : OTCQB

  15. Slide 15: Past 6 Months

    Past 6 Months Patents Key Appointments Business Deployments Acquisitions and Partnerships Development § 5 US patents filed § Appointment of Mr. Kapil Raval to § Execution of sales contract with § Successful deployment at Flow § Acquisition of chair our advisory board and Juiceworks Exhibits for US a

  16. Slide 16: Competitive Landscape

    Competitive Landscape Non- Temperature Multi-Symptom Commercialization Company AI Notes Invasive Detection Detection Stage Potentially introducing more symptom Launching detection Indicates it is AI Enabled which may mean future versions Launching Focuses its development will use AI in some on disru

  17. Slide 17: Competitive Landscape: Impairment Detection

    Competitive Landscape Impairment Commercialization Company AI Non-Invasive Notes Detection Stage Cannabix Breathalyzer Pre-commercialization Hound Marijuana Breathalyzer Unknown how it determines Focuses its development impairment and may rely on amount of cannabinoids to on disruptive technologies

  18. Slide 18: Management Team

    Sheldon Kales Dr. Rahul Kushwah Rakesh Malhotra Nandan Mishra Himanshu Ujjawal Praveen Kumar Rajiv Muradia CEO COO CFO Co-AI Lead Singh Data Analytics Lead MWB Product Lead Co-AI Lead § Expertise in operations, § PhD, Banting Fellow § CPA designation in § Artificial Intelligence § Specialization in

  19. Slide 19: Board of Directors

    Sheldon Kales Dr. Rahul Kushwah Ajit Kumar Tomas Sipos § Expertise in operations, business § PhD, Banting Fellow § Seasoned healthcare § Seasoned investment banker strategy and capital markets business leader § Developed world’s first genetic § Has held several senior positions, § Held leadership ro

  20. Slide 20: Advisory Board

    Advisory MSc, PhD MBBS, MS, DNB Board § Neurosurgeon with over 34 years’ experience in § One of India’s leading thoracic surgeons, practicing in BLK microscopic and minimal invasive neurosurgery Super Speciality Hospital, the largest stand-alone private § Sugita Fellow from Nagoya University, Japan

  21. Slide 21: Share Structure

    Shares Issued & Outstanding Incentive Stock Options Authorized Capital 100,054,149* 9,850,000 @ $0.15 Unlimited EXPIRY: APRIL 6, 2021 Most Recent Financing 350,000 @ $0.10 Fully Diluted Shares 3,296,000 @ $0.25 111,902,149 Warrants 1,648,000 @ $0.50 EXPIRY: AUGUST 2021 21 *Includes 42,682,500 shares

  22. Slide 22: Upcoming milestones and outlook

    § Pilots and rollouts in US, Canada, UK, India and other regions currently in discussion phases The Board of Directors and management team § Completion of clinical studies with Max Healthcare and potentially two other healthcare and believe the growing need for rapid, mass, early university institut

  23. Slide 23: Corporate Information and Investor Relations

    PREDICTMEDIX.COM CORPORATE INFORMATION 77 King Street West, Suite 3000 Toronto, ON, Canada M5K 2A1 INVESTOR RELATIONS Ehsan Agahi IR@predictmedix.com

PredictMedix — Investor Presentation (November 2020) on 6ix